Hyrimoz (adalimumab-adaz) — FDA-Approved Biosimilar to Humira (adalimumab)

TNF-alpha Inhibitor Biosimilar · Approved 2018 · $0–$35/mo for most insured patients

🔬 What Is Hyrimoz?

Hyrimoz (adalimumab-adaz) is an FDA-approved biosimilar to Humira (adalimumab). A biosimilar is a biological medication that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Hyrimoz (adalimumab-adaz) is a Sandoz FDA-approved Humira biosimilar available in both standard and high-concentration citrate-free formulations. Sandoz is a leading global biosimilar manufacturer, and Hyrimoz is approved for all Humira indications.

🛒 Order Hyrimoz — Direct from BiologicHealthPlus

Our pharmacist team will contact you within 2 hours to verify your prescription and insurance.

With Insurance

$0–$35/mo for most insured patients

Sandoz One Source

Uninsured / PAP

Free

Income-based assistance

Start My Order → 💬 WhatsApp 📞 Call

Hyrimoz Overview

PropertyDetails
Brand NameHyrimoz
Generic Nameadalimumab-adaz
Reference BiologicHumira (adalimumab)
ManufacturerSandoz
Drug ClassTNF-alpha Inhibitor Biosimilar
FDA Approval2018
RouteSubcutaneous injection
Approved ConditionsRheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, HS, Uveitis, JIA
Copay ProgramSandoz One Source — $0–$35/mo for most insured patients

Approved Conditions

Rheumatoid ArthritisPsoriatic ArthritisAnkylosing SpondylitisPlaque PsoriasisCrohn's DiseaseUlcerative ColitisHSUveitisJIA

Hyrimoz vs Humira (adalimumab)

Hyrimoz has been demonstrated to be biosimilar to Humira (adalimumab) through comprehensive analytical, non-clinical, and clinical studies. The FDA requires that biosimilars have no clinically meaningful differences from the reference product. Patients who are stable on Humira (adalimumab) should discuss any potential switch to Hyrimoz with their prescriber.

FactorHyrimozHumira (adalimumab)
FDA StatusBiosimilar (approved 2018)Reference biologic
Active Ingredientadalimumab-adazadalimumab
MechanismTNF-alpha InhibitorSame
Approved IndicationsSame as Humira (adalimumab)Multiple FDA-approved
Typical Patient Cost$0–$35/mo for most insured patients$0–$35/mo (varies by plan)
Yes. The FDA requires biosimilars to demonstrate there are no clinically meaningful differences in safety, purity, and potency compared to the reference product. Hyrimoz underwent rigorous clinical studies demonstrating biosimilarity to Humira (adalimumab). Your prescriber can discuss whether Hyrimoz is appropriate for your specific situation.
Many patients do switch from reference biologics to biosimilars. The decision should be made in consultation with your prescriber. Switching is generally safe for stable patients, but your doctor may want to monitor you during the transition. BiologicHealthPlus can coordinate the prior authorization for Hyrimoz and ensure a seamless supply transition.
Most commercial insurance plans and Medicare Part D cover Hyrimoz with prior authorization. In many cases, Hyrimoz may have a lower tier placement on formularies than Humira (adalimumab), potentially reducing your copay. BiologicHealthPlus verifies your insurance coverage, handles all prior authorization, and enrolls you in the Sandoz One Source copay program to minimize your out-of-pocket costs.
Without insurance, Hyrimoz costs approximately $1100/month at list price — lower than Humira (adalimumab)'s list price. Uninsured or underinsured patients may qualify for patient assistance through Sandoz One Source. BiologicHealthPlus will find every available savings option for you at no charge.

📚 Sources & Further Reading

🔗
FDA Biosimilar ApprovalsFDA
🔗
BiosimilarWikipedia
🔗
ACR Biosimilar PositionACR
🔗
Biosimilar DevelopmentNIH/NCBI
🔗
Medicare Biosimilar CoverageCMS

Medical Disclaimer: Educational content reviewed by BiologicHealthPlus Clinical Team. Last reviewed: August 2026.

Medical Disclaimer: This page is for informational purposes only. Hyrimoz requires a valid prescription. Consult your physician before making any changes to your medication. Last updated: August 2026.